Skip to main content

Advertisement

SpringerLink
Log in

Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil in Japanese patients with various subtypes of glaucoma

  • Clinical Investigation
  • Published:
Japanese Journal of Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

The present study aimed to investigate the effectiveness of adjunctive therapy involving the Rho-associated, coiled-coil-containing protein kinase (ROCK) inhibitor ripasudil in lowering intraocular pressure (IOP) in patients with different subtypes of glaucoma, on the basis of the time of IOP measurement

Study design

Retrospective study

Methods

In total, 58 patients who underwent adjunctive therapy with ripasudil at a single institution were included. They were classified into a primary open-angle glaucoma (POAG) group, an exfoliation glaucoma (XFG) group, and a secondary glaucoma associated with uveitis, or steroid glaucoma (SG), group. The average IOPs within 6 months before (pre-IOP) and after (post-IOP) the addition of ripasudil were compared among the 3 groups. The IOP values of the morning-visit and afternoon-visit groups were also compared to reflect the peak effectiveness of ripasudil.

Results

The IOP reductions in the POAG (n = 38), XFG (n = 6), and SG (n = 14) groups were −1.1, +0.5, and +0.5 mmHg, respectively. Significant reductions in IOP were observed in the POAG group (P = .014). The IOP reductions in the POAG morning-visit and afternoon-visit groups were −1.9 and +0.5 mmHg, respectively. IOP was significantly reduced in the morning-visit POAG group after treatment with ripasudil (P = .002). The IOP values measured during morning visits were lower than those measured during afternoon visits (IOP reduction: −1.3 mmHg; P = .011).

Conclusions

The findings of the present study indicate that ripasudil is effective as an adjunctive therapy for lowering IOP in patients with POAG; these reductions are more significant when measured closer to the time of peak effectiveness.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126:498–505.

    Article  Google Scholar 

  2. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268–79.

    Article  PubMed  Google Scholar 

  3. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–13.

    Article  PubMed  Google Scholar 

  4. Kook MS, Simonyi S, Sohn YH, Kim CY, Park KH. Bimatoprost 0.01% for previously treated patients with open-angle glaucoma or ocular hypertension in the Korean clinical setting. Jpn J Ophthalmol. 2015;59:325–34.

    Article  CAS  PubMed  Google Scholar 

  5. Cho SY, Kim YY, Yoo C, Lee T. Twenty-four-hour efficacy of preservative-free tafluprost for open-angle glaucoma patients, assessed by home intraocular pressure (Icare-ONE) and blood-pressure monitoring. Jpn J Ophthalmol. 2016;60:27–34.

    Article  PubMed  Google Scholar 

  6. Shoji N, Kasahara M, Iijima A, Takahashi M, Tatsui S, Matsumura K, et al. Short-term evaluation of trabectome surgery performed on Japanese patients with open-angle glaucoma. Jpn J Ophthalmol. 2016;60:156–65.

    Article  CAS  PubMed  Google Scholar 

  7. Tanaka D, Nakanishi H, Hangai M, Akagi T, Morooka S, Ikeda HO, et al. Influence of high myopia on outcomes of trabeculectomy with mitomycin C in patients with primary open-angle glaucoma. Jpn J Ophthalmol. 2016;60:446–53.

    Article  CAS  PubMed  Google Scholar 

  8. Kaneko Y, Ohta M, Inoue T, Mizuno K, Isobe T, Tanabe S, et al. Effects of K-115 (Ripasudil), a novel ROCK inhibitor, on trabecular meshwork and Schlemm’s canal endothelial cells. Sci Rep. 2016;6:19640.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Xu N, Chen SH, Qu GY, Li XD, Lin W, Xue XY, et al. Fasudil inhibits proliferation and collagen synthesis and induces apoptosis of human fibroblasts derived from urethral scar via the Rho/ROCK signaling pathway. Am J Transl Res. 2017;9:1317–25.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Honjo M, Tanihara H, Kameda T, Kawaji T, Yoshimura N, Araie M. Potential role of Rho-associated protein kinase inhibitor Y-27632 in glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2007;48:5549–57.

    Article  PubMed  Google Scholar 

  11. Futakuchi A, Inoue T, Fujimoto T, Inoue-Mochita M, Kawai M, Tanihara H. The effects of ripasudil (K-115), a Rho kinase inhibitor, on activation of human conjunctival fibroblasts. Exp Eye Res. 2016;149:107–15.

    Article  CAS  PubMed  Google Scholar 

  12. Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Suganami H, et al. Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil (K-115) combined with timolol or latanoprost. JAMA Ophthalmol. 2015;133:755–61.

    Article  PubMed  Google Scholar 

  13. Sato S, Hirooka K, Nitta E, Ukegawa K, Tsujikawa A. Additive intraocular pressure lowering effects of the Rho kinase inhibitor, Ripasudil in glaucoma patients not able to obtain adequate control after other maximal tolerated medical therapy. Adv Ther. 2016;33:1628–34.

    Article  CAS  PubMed  Google Scholar 

  14. Inoue K, Okayama R, Shiokawa M, Ishida K, Tomita G. Efficacy and safety of adding ripasudil to existing treatment regimens for reducing intraocular pressure. Int Ophthalmol. 2018;38:93–8.

    PubMed  Google Scholar 

  15. Inazaki H, Kobayashi S, Anzai Y, Satoh H, Sato S, Inoue M, et al. One-year efficacy of adjunctive use of Ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy. Graefes Arch Clin Exp Ophthalmol. 2017;255:2009–15.

    Article  CAS  PubMed  Google Scholar 

  16. Matsumura R, Inoue T, Matsumura A, Tanihara H. Efficacy of ripasudil as a second-line medication in addition to a prostaglandin analog in patients with exfoliation glaucoma: a pilot study. Clin Drug Investig. 2017;37:535–9.

    Article  CAS  PubMed  Google Scholar 

  17. Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Suganami H, et al. Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study. Acta Ophthalmol. 2015;93:e254–60.

    Article  CAS  PubMed  Google Scholar 

  18. Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Fukushima A, et al. One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension. Acta Ophthalmol. 2016;94:e26–34.

    Article  CAS  PubMed  Google Scholar 

  19. Inazaki H, Kobayashi S, Anzai Y, Satoh H, Sato S, Inoue M, et al. Efficacy of the additional use of ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled under maximum medical therapy. J Glaucoma. 2017;26:96–100.

    PubMed  Google Scholar 

  20. Naumann GO, Schlötzer-Schrehardt U, Küchle M. Pseudoexfoliation syndrome for the comprehensive ophthalmologist: intraocular and systemic manifestations. Ophthalmology. 1998;105:951–68.

    Article  CAS  PubMed  Google Scholar 

  21. Rohen JW, Linnér E, Witmer R. Electron microscopic studies on the trabecular meshwork in two cases of corticosteroid-glaucoma. Exp Eye Res. 1973;17:19–31.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Miyata Eye Hospital, 6-3 Kurahara, Miyakonojo, Miyazaki, 885-0051, Japan

    Takashi Komizo, Takashi Ono, Akiko Yagi & Kazunori Miyata

  2. Department of Ophthalmology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo, 113-8655, Japan

    Makoto Aihara

Authors
  1. Takashi Komizo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takashi Ono
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Akiko Yagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kazunori Miyata
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Makoto Aihara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Makoto Aihara.

Ethics declarations

Conflicts of interest

T. Komizo, Lecture fee (Kowa); T. Ono, Lecture fees (Bayer, Kowa, Santen, Senju); A. Yagi, None; K. Miyata, Grant (Novartis, Otsuka, Santen, Senju), Lecture fees (Kowa, Novartis, Otsuka, Pfizer, Santen, Senju); M. Aihara, Grant (Alcon, Pfizer), Consultant fees (Crewt Medical Systems, Glaukos, HOYA, Otsuka, Santen, Senju, WaKamoto), Lecture fees (Abbot, Alcon, Allergan, Crewt Medical Systems, HOYA, JFC Sales Plan, Kowa, Nitten, Otsuka, Pfizer, Santen, Senju, WaKamoto).

Additional information

Corresponding author: Makoto Aihara

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Komizo, T., Ono, T., Yagi, A. et al. Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil in Japanese patients with various subtypes of glaucoma. Jpn J Ophthalmol 63, 40–45 (2019). https://doi.org/10.1007/s10384-018-0635-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10384-018-0635-0

Keywords

Search

Navigation